{"type":"video","version":"1.0","html":"<iframe src=\"https://www.loom.com/embed/a8baa478d04a44f4a740c38d5aa03e30\" frameborder=\"0\" width=\"1298\" height=\"973\" webkitallowfullscreen mozallowfullscreen allowfullscreen></iframe>","height":973,"width":1298,"provider_name":"Loom","provider_url":"https://www.loom.com","thumbnail_height":973,"thumbnail_width":1298,"thumbnail_url":"https://cdn.loom.com/sessions/thumbnails/a8baa478d04a44f4a740c38d5aa03e30-da32ab3ec96302d3.gif","duration":86.319,"title":"Why a Cancer Test Trial Missed Its Endpoint","description":"This Loom discusses a cancer screening research question audit and why the protocol missed its endpoint. It explains that the problem was the wrong research question for a low prevalence population, where a composite cancer endpoint created many false alarms among the general NHS screening population. The hypothesis that sounded reasonable was reviewed and found to be flawed, with a “phlob of a protocol lock” noted. The logic is that positive tests shift from mostly false alarms in the general population to flipping in a higher risk or richer group, which the trial missed due to question design rather than technology."}